drugset / Trial / NCT01263366

Exploratory Study of Norepinephrine to Prevent Radiodermatitis in Breast Cancer Patients

NCT01263366

NaSingle-groupOpen-labelSupportive care

Summary

This study, a nonrandomized open-label Phase I safety and exploratory study, will evaluate the safety of topical norepinephrine in post-surgical breast cancer patients who are undergoing radiation therapy. The study will also provide information about whether topical norepinephrine can prevent or decrease the severity of the radiation dermatitis experienced by these patients.

Timeline

Start
2011-01
Primary completion
2013-04
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Norepinephrine Other / unclassified 1.6 ml Topical
Subject Norepinephrine Other / unclassified 4.6 ml Topical

Indications